Men and women aged 18-75 years old with a diagnosis of hidradenitis suppurativa (HS) and disease lasting for at least 1 year, may qualify to participate in this study. Individuals must have moderate to severe hidradenitis suppurativa with 4 lesions or more in at least 2 distinct areas.
Participants must first commit to a 4-week trial of oral antibiotics in which the medication yields an inadequate response. Eligible participants will receive investigational oral medication (active drug or placebo). Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last up to 26 weeks and include about 10 visits to the study centre.
Email Tina Craig, Clinical Research Coordinator at DermEffects to register.